Sysmex Inostics has developed a liquid biopsy test for the detection of Minimal Residual Disease (MRD) in Acute Myeloid Leukemia (AML). The company’s new test, available for pharmaceutical clinical trial sponsors, uses a targeted next generation sequencing (NGS) panel.
"The new test, AML-MRD-SEQ, offers clinical trial sponsors, and eventually physicians and patients, an early signal for the presence of cancer cells following initial therapy," said Shinichi Sato, CEO of Sysmex Inostics.
The new test is available through Sysmex Inostics' lab services in Baltimore.
AML-MRD-SEQ offers a panel covering 68 regions across 20 genes, including established MRD markers such as NPM1, and demonstrating significant potential for use as an investigational tool for other markers with prognostic values that are not yet well-established.
AML is one of the deadliest blood cancers, resulting in more than 10,000 lives lost in the U.S. each year, the company said. Because AML relapses usually result in a poor prognosis, it is necessary to test patients for MRD after initial treatment as a prognostic indicator of therapeutic effectiveness and relapse risk.
Sysmex Inostics is a subsidiary of Sysmex Corporation.
In July 2021, Sysmex Corporation announced a global strategic alliance with QIAGEN to provide custom cancer companion diagnostics (CDx) utilizing Plasma-Safe-SeqS technology. The alliance is intended to promote early clinical implementation of Sysmex Inostic's technology to expedite clinical trial timelines for pharmaceutical companies that develop molecularly targeted drugs for cancer.
